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Abstract
Epigenomic dysregulation is a common pathological feature in human hematological malignancies. H3K9me3
emerges as an important epigenomic marker in acute myeloid leukemia (AML). Its associated methyltransferases, such
as SETDB1, suppress AML leukemogenesis, whilst H3K9me3 demethylases KDM4C is required for mixed-lineage
leukemia rearranged AML. However, the specific role and molecular mechanism of action of another member of the
KDM4 family, KDM4A has not previously been clearly defined. In this study, we delineated and functionally validated
the epigenomic network regulated by KDM4A. We show that selective loss of KDM4A is sufficient to induce apoptosis
in a broad spectrum of human AML cells. This detrimental phenotype results from a global accumulation of H3K9me3
and H3K27me3 at KDM4A targeted genomic loci thereby causing downregulation of a KDM4A-PAF1 controlled
transcriptional program essential for leukemogenesis, distinct from that of KDM4C. From this regulatory network, we
further extracted a KDM4A-9 gene signature enriched with leukemia stem cell activity; the KDM4A-9 score alone or in
combination with the known LSC17 score, effectively stratifies high-risk AML patients. Together, these results establish
the essential and unique role of KDM4A for AML self-renewal and survival, supporting further investigation of KDM4A
and its targets as a potential therapeutic vulnerability in AML.
Introduction
Epigenetic regulators are frequently mutated in acute
myeloid leukemia (AML), leading to epigenomic altera-
tions1. Inhibitors that target epigenetic modulators to
rectify epigenomic abnormalities represent valid ther-
apeutic strategies. Further understanding of how epige-
netic dysregulation in AML contributes to leukemogenesis
may uncover tractable therapeutic targets and biomarkers
for AML patient treatment and/or prognostic evaluation.
Polymerase-associated factor 1 (PAF1), a core compo-
nent of the PAF complex (PAFc) is essential in AML2–4.
PAFc mediated recruitment of the H3K9 methyl-
transferases, such as SETDB1 antagonizes Mixed-Lineage
Leukemia (MLL) signaling, and inhibition of SETB1
promotes AML cell proliferation5,6.
Primary AML blasts from patients with poor prognosis
feature global H3K9me3 hypomethylation7 positing an
oncogenic role for H3K9me3 demethylases in AML.
Cheung et al. identified an H3K9me3 demethylase,
KDM4C as a cofactor of the PRMT1 complex in MLL
rearranged (MLLr) and MOZ-TIF2 AML8. Simultaneous
knockout (KO) of all three members of the Kdm4 family
(kdm4a/b/c) in mice attenuates MLL-AF9 AML9, indi-
cating roles for the Kdm4 family in murine myeloid leu-
kemia. However, the therapeutic benefit of targeting the
KDM4 family in human AML is not well understood.
Our previous lentiviral knockdown (KD) screen target-
ing epigenetic regulators in 12 human AML cell lines
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representing several AML subgroups found that KMD4A
KD leads to significant suppression of leukemia cell pro-
liferation10. KDM4A has different roles in normal tissue
development compared to other members of the KDM4
family; it is amplified/overexpressed in various malig-
nancies including AML (Fig. S1A) and correlates with
poor outcome in ovarian cancer11,12. Herein we demon-
strate that KDM4A KD induces AML apoptosis by a
unique mechanism to KDM4C in myeloid leukemia.
Apoptosis results from a global accumulation of
H3K9me3 and H3K27me3 at KDM4A genomic loci
thereby causing downregulation of a KDM4A-PAF1-
mediated oncogenic program, including a 9-gene sig-
nature enriched with leukemia stem cell (LSC) activity,
which can stratify high-risk patients. These findings sup-
port an essential and unique role of KDM4A for AML cell
self-renewal and survival.
Materials and methods
Reagents, plasmids, and virus manufacture
Puromycin, IOX1dev, and lentiviral constructs for KD
experiments (Supplemental Table) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). IOX1 was from
Tocris (4464). pLenti-HA-KDM4A wt and mut (H188A/
E190A) were a gift from Dr. Gary Spencer (CRUK Man-
chester Institute). Lentiviral and retroviral supernatants
were prepared, and leukemic human and murine cells
transduced with viral particles as previously described10.
A list of antibodies used in flow cytometry and Western
blot/immunoprecipitation and immunofluorescence
staining is in the Supplemental Table.
Culture of cell lines and primary cells
Leukemia cell lines were from DMSZ (Braunschweig,
Germany) and grown in RPMI (10% FBS and 2mM L-
Glutamine) at 37 °C in 5% CO2. They were recently
authenticated and tested for mycoplasma contamination.
Murine and human primary AML and normal BM sam-
ples were cultured in serum-free media (SFM) (H5100,
Stem Cell Technologies, UK) supplemented with appro-
priate cytokines as described13. Murine MLL-AF9 AML
cells were leukemic BM cells extracted from a mice cohort
with MLL-AF9 AML established by Somervaille et al.14,
and cultured in the conditional medium with mIL-3
(100 ng/ml). Cytokines purchased from PeproTech
(London, UK).
Cell proliferation, apoptosis, and cell cycle analysis
Cell viability was measured by cell count using trypan
blue dye (Sigma, T8154) /hemocytometer or resazurin
(Alamarblue dye, Sigma) with the Envision Fluorescent
Reader (Perkin Elmer). Apoptosis was assessed using
Annexin-V/Dead Cell Apoptosis Kit (V13241, Thermo-
Fisher) and cell cycle analysis with PI/RNase Staining
solution (F10797, ThermoFisher) as per manufactures’
instructions. Data were acquired using an LSRII flow
cytometer and an Aria III flow cytometer (BD Biosciences,
UK) and analyzed using FlowJo software (Tree Star
Inc., USA).
Protein extraction and Western blot
Cell pellets were suspended in fresh lysis buffer (50mM
Tris-HCl, pH7.4, 150mM NaCl, 1% Triton X-100, 0.5%
Sodium Deoxycholate, 0.5% SDS, 0.1% β-mercaptoethanol,
10mM Sodium butyrate, 10mM nicotinamide, 1 mM
PMSF, 1× phosphatase inhibitor, 1× protease inhibitor) at
30 μl per 106 cells and lysed on ice. Protein Lysates were
quantified using Pierce Coomassie Plus Bradford and ran
in NuPAGE™ 4–12% Bis-Tris Protein Gels (Invitrogen) as
per products’ instructions. Only one loading control is
used when Western blot analyses with multiple antibodies
have been done sequentially in the same membrane.
Immunofluorescence (IF) staining
6 × 104 cells per condition were incubated on poly-L-
lysine coated Hendley-Essex 12 well glass microscope
slides for 1 h before being fixed in 4% formaldehyde in
PBS. The cells were permeabilized in 0.5% Triton-X-100
PBS followed by 2 h of blocking in 5% BSA, 0.2% Triton-
X-100 TBS. Primary antibody was applied overnight in a
humidified chamber at 4 °C. Appropriate secondary anti-
body (1:500 dilution) was applied for further 1 h incuba-
tion at room temperature after removal of a primary
antibody using PBS 0.1% Tween 20. Antifade mountant
with DAPI reagent (Thermo Fisher #P36962) was used to
seal each sample and images were captured on the Zeiss
Axioimager M1 Epifluorescence and Brightfield Micro-
scope. CellProfiler v2.2.0 image analysis software (Cell-
Profiler) was used to quantify IF signals.
Colony-forming cell assay
Colony-forming cell (CFC) assay for murine cells was
performed by plating 1000 cells on methylcellulose
(MethoCult M3434, Stem Cell Technologies). Colony
Assay for human CD34+ hematopoietic stem and pro-
genitor cells (HSPC) and AML patient cells were per-
formed by plating 10000 cells and 3000 cells, respectively,
on methylcellulose (MethoCult H4434, Stem Cell Tech-
nologies). CFU-GM (Granulocyte/Macrophage), M(Mac-
rophage), and E(Erythroid) colonies were enumerated
10 days after seeding.
Murine transplantation experiments
Mice experiments were approved by the local animal ethics
board and performed under a project license issued by the
United Kingdom Home Office, in keeping with the Home
Office Animal Scientific Procedures Act, 1986. Non-obese
diabetic. Cg-Prkdc scid Il2rgtm1Wjl/SzJ (NSG) mice were
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purchased from Jackson Laboratories (Bar Harbor, ME,
USA) for transplantation as previously described10. Primary
AML patient samples for xenograft transplantation were
unfractioned primary blasts from our and Manchester bio-
bank collections. Control or KDM4A KD human AML
THP1 cells or primary AML patient blasts were FACS sorted
40 h following lentiviral infection and immediately trans-
planted into sub-lethally irradiated (450 cGy) NSG mice of
6–8-week-old, mixed-sex (10,000 THP1 cells or 10^6 pri-
mary AML cells) via tail vein injection.
RNA isolation, quantitative PCR, RNA-seq, and ChIP-seq
RNA was extracted using QIAshredder™ columns and
RNeasy Plus Microkit™ (Qiagen). RNA-seq libraries were
produced using the TruSeq® stranded mRNA kit (Illu-
mina) and sequenced on the Illumina NextSeq™ 500
platform. For ChIP-seq, DNA was purified using Diag-
enode’s iPure kitv2 and libraries made using the TruSeq
ChIP Library Preparation Kit according to the manu-
facturer’s instructions. For QPCR, reverse transcription
was carried out using Invitrogen SuperScript III First-
Strand Synthesis kit. A SYBR® green-based fluorescent
system was used to quantify dsDNA using the Applied
Biosystems 7900 HT Fast Real-Time PCR system. Each
qPCR plate included technical triplicates of each specific
target alongside two housekeeping genes (GAPDH and ß-
Actin). Delta-Delta CT method was used for analysis of
gene expression against control. RNA-seq and ChIP-seq
reads were mapped to the hg19 human genome or mm9.
Transcript abundances were calculated in transcripts per
million (TPM) using Kallisto15. SICER was used for peak
calling on default settings. Both data files are available in
the Gene Expression Omnibus (GEO): GSE125376.
Gene signature construction
The KDM4A-9 signature score is calculated as shown
below using the least absolute shrinkage and selection
operator (LASSO) linear regression16,17.




Where xi and ri denote the gene expression and
coefficient of the ith gene (out of the total 9 genes) in
the signature, respectively. Specifically, KDM4A-9 score
= (TPM2 × 0.097292)+ (CD82 × 0.038719)+ (SLC29A2 ×
0.167487)+ (INF2 × 0.150025)+ (STAR ×−0.13354)+
(ACP6 × 0.04633)+ (IFI6 × 0.015753)+ (MROH6 ×
0.086738)+ (GSDMD × 0.008289).
Correlating the KDM4A-9 signature and LSC activity
LSC enrichment classification and raw expression data
from AML samples (GSE76008)17 were analyzed using the
lumi 2.36.0 package. Intensity values were normalized by
Robust spline normalization. The diagnostic capability of
each gene signature to predict LSC activity across AML
samples (GSE76008) was assessed by ROC (Receiver
operating characteristic) curve analysis. The Youden
index was used to identify the optimal cut-off value.
Construction of KDM4A-9 and LSC17 combined score
Min-Max scaling of the KDM4A-9 and LSC17 scores
was performed prior to the linear summation of KDM4A-
9 and LSC17 scores for each patient to generate a com-
bined KDM4A-9/LSC17 score.
Xnew ¼ Xi min Xð Þmax Xð Þ min Xð Þ
Network construction and visualization
To visualize the connections between the LSC17 and
KDM4A-9 signature genes, as well as KDM4A and PAF1
in AML patients, a filtered edge list (TOM ≥ 0.05)18 was
constructed. An undirected network graph was generated
using the graph.edgelist function from the igraph 1.2.5
package.
Motif analysis
Motif enrichment analysis of 400 bp length DNA
sequences centered over the TSS of KDM4A or PAF1
bound (FDR ≤ 0.01) and DE (padj ≤ 0.05, DE ≥ 0.5 or
≤−0.5) genes was performed using MEME-ChIP (http://
meme-suite.org/tools/meme-chip).
Statistical analysis
Normally distributed groups were compared using a
two-tailed student t-test unless stated otherwise. Survival
probabilities estimated by Kaplan-Meier method. For
RNA-seq counts, a pseudo-count of 1 was added prior to
log2-transformation. Statistical significance of differential
gene expression was assessed by Welch’s t-test unless
otherwise stated. For RNA-seq, differential expression
analysis was performed using the DESeq2 1.26.0 R pack-
age. Statistics were calculated using R-3.6.1.
Results
KDM4A is required for the survival of human and murine
AML cells
KDM4A expression is unique (Fig. S1B) being highly
enriched in AML-LSC+ populations (Fig. S1C), suggesting
that KDM4A is important for LSC, which are negatively
correlated with AML patient survival. We performed
lentivirus shRNA KD of KDM4A, KDM4B, and KDM4C
in human AML MLL-AF9-driven THP1 cells to confirm
its essential role. KDM4A KD THP1 cells exhibited the
greatest decrease in cell proliferation compared to non-
targeting cells (NTC) (Fig. 1A–C). Consistent with
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Fig. 1 (See legend on next page.)
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previous work, lentiviral KD of KDM4C had an inhibitory
effect on cell proliferation8 (Fig. 1A). CFC potential was
positively correlated with the KDM4A in a dose-
dependent manner when five KDM4A KD shRNA tar-
geting constructs were compared (Fig. 1D). KDM4A KD
induced apoptosis (Fig. 1E and S1D) rather than cell cycle
arrest (Fig. S1E). These results were further confirmed in
primary patient blasts (Fig. 1F and G) and murine AML
cells (Fig. 1H). Importantly, we determined the impact of
KDM4A KD on AML initiation in vivo by transplanting
KDM4A KD THP1 cells (Fig. 1I) or primary AML cells
(Fig. 1J–K and S1F–S1H) into recipient NSG mice.
Control cells induced short-latency disease with spleno-
megaly (Fig. 1K). Loss of KDM4A significantly prolonged
overall survival (OS) of mice with only one mouse suc-
cumbing to leukemia over the follow-up period by either
KDM4A#1 KD or KDM4A#2 KD (Fig. 1J–K and S1F–
S1H). Together, these data demonstrate a specific and
essential role for KDM4A in AML cell survival.
Targeting KDM4A’s demethylase activity inhibits AML cell
proliferation
Functional rescue experiments determined that the
demethylase activity of KDM4A is required for AML.
Forced-expression of wild-type human KDM4A rescued
the clonogenic activity of AML cells transduced with
kdm4a KD virus (Fig. 2A and B). This rescue phenotype
was not observed by a catalytically inactive mutant of
KDM4A (KDM4AH188A/E190A)19,20 (Fig. 2A and B) in
murine MLL-AF9 cells. Next, we assessed KDM4A sub-
strates H3K9me3 and H3K36me3 in KDM4A KD
THP1 cells. There was an increase in H3K9me3 shown by
immunoblotting (Fig. 2C and D) and immunofluorescent
staining (Figs. S2A–S2B). No significant changes in
H3K36me3 were observed (Fig. 2C–D; S2A–S2B), sug-
gesting H3K9me3 is the primary target of KDM4A in
THP1 cells. In addition, there was a marked elevation of
H3K27me3 in KDM4A KD THP1 cells (Fig. 2C–D; S2A–
S2B) and two further KDM4A KD human MLLr-AML cell
lines (Figs. S2C–S2D).
We next investigated whether KDM4A is dispensable for
normal hematopoiesis. Our data showed no significant loss
of colonies in kdm4a KD normal murine BM c-kit+ cells in
CFC assays (Fig. 2E and F; S2E). Similarly, reduced levels of
KDM4A in human CD34+ HSPCs from healthy donors are
tolerated (Fig. 2G and H; S2F) with fewer colonies due to a
reduction of CFU-GM in KDM4A KD #1 cells. Although a
KDM4A specific inhibitor is lacking, there are several pan-
KDM4 inhibitors available including IOX121 and IOX
derivatives (IOX1dev)22,23. These displayed significant
inhibitions of cell proliferation in THP1 cells and primary
AML patient blasts, inducing differentiation and apoptosis
(Figs. S3A–S3G) with minimum effect on normal human
CD34+ BM HSPCs (Fig. S3E). These phenotypes were
accompanied by an increased level of H3K9me3 and
H3K27me3 (Fig. S3H), suggesting the anti-leukemic effect
was due to KDM4A inhibition.
PAF1 identified as a KDM4A co-regulator is required for
human AML cell survival
To determine the impact of KDM4A on global gene
expression, we compared the transcriptome of KDM4A
KD THP1 cells with NTC control by RNA-seq. 3375
differentially expressed (DE) genes were significantly
deregulated following depletion of KDM4A (Log2 fold
change (FC) ≥0.5 or ≤−0.5; adj. p ≤ 0.05; Fig. 3A; Sup-
plemental file). 67% (2274 out of 3375) were direct targets
of KDM4A; ChIP-seq revealed that KDM4A bound at
their TSS (Supplemental file). 61% (1387 out of 2274) of
putative KDM4A direct target genes were downregulated
associated with the enrichment of transcriptional repres-
sive marks at H3K9me324 and H3K27me325 (Fig. 3A).
(see figure on previous page)
Fig. 1 KDM4A is required for the functional potential of human and murine AML cells. A–E Human THP1 AML cells were transduced with
lentiviruses targeting KDM4A or other KDM4 family members for KD (♯1 and ♯2 represent individual distinct lentiviruses targeting genes for KD as
indicated), or a non-targeting control (NTC), using KD of MLL andMEN1, as positive controls, which are essential genes for AML cell proliferation. All bar
charts show mean ± s.e.m. A Resorufin signal after 4 days of individual KDM4 family member KD relative to NTC control cells (n= 3); *p < 0.01 for
comparison of each KD versus NTC. B Expression of KDM4A/B/C/D in indicated KD cells relative to NTC control cells (n= 3); *p < 0.001. C Representative
immunoblot showing KDM4A KD in THP1 cells (n= 3). D Scatter plot shows the correlation of KDM4A KD with inhibition of frequency of colony-
forming cells (CFC) enumerated following 10 days in semisolid culture (n= 3), as determined by QPCR; *p < 0.001. E Percentage of apoptotic cells
determined by Annexin V+/ 7AAD+/− staining on day 4 of liquid culture after puromycin selection (n= 3); *p < 0.001. F–G The indicated primary
unfractioned patient blasts were transduced with lentiviruses targeting KDM4A for KD, or an NTC. Primary AML cells used include BB160, containing t
(9;11) (MLL-AF9) chromosomal translocation and BB86 (normal cytogenetics, non-MLL) (BB number is the Manchester Cancer Research Centre Biobank
sample identifier). All bar charts show mean ± s.e.m. F CFC frequencies of primary human AML blasts (n= 3) following lentivirus infection, puromycin
selection, and initiation of KDM4A KD; *p < 0.0001. G Representative images from F. H CFC frequencies of primary murine MLL-AF9 AML cells following
KDM4A depletion (n= 3); *p < 0.0001. I Survival curves of NSG mice transplanted with 10,000 KDM4A KD or NTC THP1 cells (n= 5 per cohort); p by log-
rank test. J Survival curves of NSG mice transplanted with 106 KDM4A KD or NTC primary AML cells (BB160, n= 7 per cohort); p by log-rank test.
K Spleen weights of mice from J with a representative image of the spleen. p by one-way ANOVA, F= 34.13045.
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Fig. 2 Targeting KDM4A’s demethylase activity inhibits AML cell proliferation. A CFC frequencies for control and kdm4a KD cells from the indicated
murine MLL-AF9 cells overexpressing empty vector (MTV) or wild-type human HA-tagged-KDM4A or an enzymatically inactive mutant of human HA-tagged-
KDM4A (KDM4Amut H188A/E190A) (n= 3); *p<0.001, NSp>0.05. Representative immunoblot below bar plot shows the overexpression of wild type (wt) and
mutant (mut) human HA-tagged KDM4A in correlated MLL-AF9 cells labeled, detected by HA antibody. B Bar chart showingmean± s.e.m. an expression of kdm4a
by QPCR in kdm4a KD cells from (A) relative to NTC in murine MLL-AF9 leukemic cells (n= 3); *p< 0.01. C Representative immunoblots with indicated antibodies
showing expression of indicated proteins in THP1 cells 72 h following initiation of KDM4A KD (n= 3). D Immunoblot quantification of signal intensity relative to H3
total from C. E–H The indicated primary human and murine AML cells were transduced with lentiviruses targeting KDM4A or kdm4a for KD, or an NTC. All bar
charts showmean± s.e.m. CFC frequencies of (E) primary normal murine c-kit+ BM cells for NTC and kdm4a KD (n= 3) or (G) primary normal human CD34+ HSPC
cells for NTC and KDM4A KD cells (n= 3); *p<0.01. F and H are representative images from (E) and (G), Scale bar represents 100 µm and 200 µm, respectively.
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Fig. 3 (See legend on next page.)
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To provide insights into the survival pathways regulated
by KDM4A, we performed gene-set enrichment analysis
(GSEA) and revealed significant enrichment of genes
regulated by PAFc26–28 (Fig. 3B). This is consistent with
downregulation of PAF1, following KDM4A KD at the
transcript (Fig. 3C and D) and protein (Fig. S4A) level in
human MLLr-AML cell lines, and primary patient blasts.
PAF1 KD phenocopied KDM4A KD in MLLr-AML cells,
inducing significant apoptosis (Fig. 3E–G; S4B) and loss of
CFU potential (Fig. 3H). Together, these data suggest loss
of KDM4A impairs PAF1 function to maintain leukemic
cell survival, supporting PAF1 as an important cofactor of
KDM4A in human AML.
KDM4A-PAF1 maintains appropriate expression of the
MLLr-fusion oncogenic program in MLLr-AML
Our ChIP-seq data reveal substantial overlap amongst
PAFc26, MLL-AF929, and KDM4A binding sites (Fig. 4A–
C). Specifically, KDM4A bound the PAF1 promoter
region (Supplemental file), suggesting a direct regulatory
mechanism. There is no enrichment of either histone
methylation mark at non-KDM4A binding genomic loci
(Fig. 4D and E), indicative of a human KDM4A-specific
epigenomic profile. In marked contrast, there is a global
gain of both H3K9me3 and H3K27me3 upon KDM4A KD
in THP1 cells at KDM4A binding sites (Fig. 4F and G;
5A), including the genomic loci of PAF1 and its targets
(Fig. 5B). These were validated by ChIP-QPCR in cell lines
and primary patient blasts (Fig. 5C and D).
Furthermore, genes with significant expression changes
following KDM4A silencing were also enriched in direct
PAF1 target genes26 (Fig. 5E), suggesting a transcriptional
network co-regulated by both KDM4A and PAF1. This
notion is supported by the fact that KDM4A bound
promoters share almost identical enrichment of tran-
scription factor (TF) binding motifs as the ones bound by
PAF1, including homeobox (HOX) TFs, such as TLX2
and DBX (Fig. 5F). Further GSEA analysis on the
overlapped DE genes between KDM4A KD and PAF1 KD
revealed a significant downregulation of MLLr fusion
target genes30, as well as HOX family target genes31
including notably the pro-survival gene, BCL2, and
marked upregulation of a mature hematopoiesis pro-
gram32 (Fig. 5G) and pro-apoptotic gene, BCL2L11 (BIM).
Although the expression of HOXA9 itself was not affected
by either KD, our data suggest KDM4A and PAF1 co-
regulate their downstream targets in a parallel manner.
A core 9-gene signature downstream of KDM4A strongly
associated with LSC activity and clinical outcome
Supporting the collaborative role of KDM4A-PAF1 in
AML, KDM4A expression is highly associated with PAF1
expression in patient datasets (Fig. 6A and B); KDM4A-
PAF1 expression can identify patients with inferior OS
(Fig. 6C). KDM4A KD induced a significant reduction of
cell proliferation in human AML cell lines representative
of different subtypes (Fig. S5A), coupled with an increase
in apoptosis and loss of CFC potential (Figs. S5B and
S5C). This evidence suggests that KDM4A is required
across AML.
These data led to our hypothesis that a core gene
expression signature (GES) downstream of the KDM4A-
PAF1 regulatory axis, is associated with AML patient
outcomes compared with the known LSC score, LSC1717.
For this, we utilized LASSO regression analysis16,17,33 on
KDM4A regulated genes (KDM4A KD Log2FC ≥1 or ≤−1;
adj. p ≤ 0.05; Supplemental file) and defined a KDM4A-9
score (Fig. 6D). High KDM4A-9 was highly associated
with poor OS in AML cohorts (Fig. 6E–H) independent of
age, cytogenetic risk score, and frequent mutation status.
The robust prognostic value of KDM4A-9 indicates that
the score may be related to the important biological
activities of AML-LSCs. Indeed, KDM4A-9 correlates
with the LSC17 score of AML samples and over 75% of
KDM4A-9 high score fractions are LSC+ (Fig. 7A),
therefore KDM4A-9 is a strong predictive indicator of
(see figure on previous page)
Fig. 3 PAF1 identified as a cofactor of KDM4A in MLLr-AML. A Volcano plot showing global changes in gene expression following the loss of
KDM4A compared to NTC control THP1 cells as identified by RNAseq. The absolute number of upregulated or downregulated genes that are bound
by KDM4A is indicated at the top right and left side of the plot, respectively (KDM4A bound: FDR ≤ 0.01, gene expression: log2 FC ≥0.5 or ≤−0.5;
adjusted (adj. p) p ≤ 0.05). B GSEA show overlapping transcriptional consequences following the loss of KDM4A or PAF1 in THP1 cells. Specifically,
genes repressed (left panel) or activated (right panel) are upregulated and downregulated, respectively, following the loss of KDM4A26. C–H
THP1 cells and other indicated human AML cells were transduced with lentiviruses targeting KDM4A or PAF1 for KD, or an NTC. All bar charts show
mean ± s.e.m. C Bar chart showing relative expression of KDM4A and PAF1 by QPCR in comparison with NTC control cells following KDM4A KD using
two different shRNA constructs ♯1 and ♯2 in THP1 cells (n= 3) (D) and the other indicated human AML cells and primary AML cells include PX21,
containing t(6;11)(MLL-AF6) chromosomal translocation and PX30 t(10;11)(MLL-AF10) (PX number is the Paul O’Gorman Leukaemia Research Centre
Biobank sample identifier) (n= 3) (F); *p < 0.01. E–F Percentage of live cell counts in comparison with NTC control (E) in THP1 cells 4 days following
lentiviral infection (n= 3) and (F) in the indicated human MLLr-AML cell lines and AML primary cells following KDM4A KD in comparison with NTC
control cells (n= 3) (I) *p < 0.01. G Bar chart showing relative expression of PAF1 by QPCR in comparison with NTC control cells following PAF1 KD
using two different shRNA constructs ♯1 and ♯2 in (E and F). H Bar chart showing the loss of CFC frequencies of indicated human AML cell lines and
primary patient samples (n= 3) following lentivirus infection, puromycin selection, and initiation of PAF1 KD; *p < 0.001.
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Fig. 4 KDM4A-PAF1 co-regulates essential MLLr-fusion oncogenic transcriptional program. A Feature distribution of KDM4A ChIP-seq peaks in
the THP1 cell genome. B Metagene plots showing a distinct peak in KDM4A normalized ChIP-seq signal in reads per million mapped reads (RPM) at
transcription starting sites (TSS) in WT THP1 cells. C Venn diagram showing the overlap between binding sites of KDM4A, PAF1c26, and MLL-AF929 in
THP1 cells as determined by ChIP-seq; p by hypergeometric test. D–G Metagene plots showing enrichment of H3K9me3 (F) and H3K27me3 (G) at
KDM4A bound TSS compared to unbound TSS (D and E) following KDM4A KD by ChIP-seq.
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Fig. 5 (See legend on next page.)
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AML-LSC activity (Fig. 7B). Interestingly, there is no
overlap between these two gene signatures. A combined
signature score (KDM4A-9/LSC17) achieves an optimal
balance between specificity and sensitivity (Fig. 7C)
overcoming the limitations of either score alone with an
improved ability to predict survival over LSC17 (Fig. 7D
and E).
KDM4A binds at the promoter regions of KDM4A-9
genes, whereupon H3K9me3 and H3K27me3 are enriched
after KDM4A KD (Fig. 8A; Supplemental file), suggesting
direct regulation. In addition to the QPCR validation in
human AML cell lines and primary AML blasts following
KDM4A KD or PAF1 KD (Fig. 8B), we observed that the
majority of KDM4A-9 genes show correlation with
KDM4A and PAF1 expression in patient AML cohorts
(Fig. 8C and D). Furthermore, weighted gene correlation
network analysis (WCGNA)34 demonstrated a strong
relationship between KDM4A, PAF1, and the KDM4A-9
and LSC17 GESs across AML. This network possessed
high topological overlap (topological overlap matrix
(TOM) ≥0.05)) with KDM4A as a highly connected node
(Fig. 8E) suggesting that KDM4A-PAF1 regulates the
KDM4A-9/LSC17 network in AML.
KDM4A has a distinct function to another KDM4 family
member, KDM4C in AML
Previously, Cheung et al. showed that KDM4C is
required for MLLr-AML cell survival8, indicating an
overlapping role of KDM4A and KDM4C in AML.
However, forced-expression of wild-type human KDM4C
failed to rescue the clonogenic activity of murine MLL-
AF9 AML cells transduced with kdm4a KD virus (Figs.
S6A and S6B), suggesting KDM4A has a distinct role from
that of KDM4C. This is in line with previously reported
data showing no increase of global H3K27me3 level upon
pharmacological inhibition of KDM4C in MLLr-AML
cells8. Consistently, at the molecular level, KDM4A KD
led to transcriptional changes distinct from KDM4C KD
via GSEA comparison (Fig. S6C), further supporting a
unique role for KDM4A compared to KDM4C in human
AML. In particular, KDM4A KD has no significant impact
on gene expression of two established targets of KDM4C,
HOXA9, and MEIS1 in human MLLr-AML cells. These
results are also validated by Q-PCR using shRNAs tar-
geting HOXA9 as control (Fig. S6D). More importantly,
kdm4c KD had no impact on PAF1 expression, nor its
associated genes targeted by KDM4A including KDM4A-
9 and LSC17 GESs (Fig. S6E). Together, these data
demonstrate an essential role of KDM4A in human AML.
Discussion
Previous reports indicate that the KDM4 family is
required for normal hematopoiesis9,35, whilst loss of
individual members is tolerated in normal cells35 high-
lighting the importance of identifying KDM4 family
members that are essential for the survival of AML cells.
Our data demonstrate KDM4A is unique; it is selectively
required for AML cell survival, with no negative effect on
normal hematopoiesis offering a therapeutic window.
Lack of tractable enzymatic activities limits the potential
of PAF1 or other subunits of the PAFc as therapeutic
targets in cancer. Herein, we identify a novel KDM4A-
PAF1 signaling axis co-regulating oncogenic transcrip-
tional networks in human AML, providing a way to
eliminate leukemic cells with broad therapeutic applica-
tions. Our study provides a strong rationale for the further
development of KDM4A inhibitors, presenting a pro-
mising strategy for novel epigenetic-based therapy
in AML.
KDM4A-9 shows strong therapeutic implications com-
parable with LSC1717. A high KDM4A-9 score may reflect
an important biological property of KDM4A in leuke-
mogenesis. The function of the KDM4A-9 genes in leu-
kemogenesis is unknown; except Tetraspanin (CD82)36,37
which plays an important role in AML. Corroborating
recent findings5,6, our data suggest KDM4A regulates
H3K9me3 to direct leukemogenesis. H3K9me3 has
emerged as a key player in repressing lineage-
(see figure on previous page)
Fig. 5 KDM4A-PAF1 maintains appropriate expression of the MLLr-fusion oncogenic program in MLLr-AML. A Heatmap showing normalized
ChIP-seq signal of H3K9me3 and H3K27me3 at TSS across all genes in KDM4A KD and NTC THP1 cells ordered by KDM4A enrichment. B Genomic
snapshot demonstrates KDM4A occupancy at the PAF1 promoter region and enrichment of H3K9me3 and H3K27me3 signal throughout the PAF1
gene body and promoter upon KDM4A KD in comparison with NTC control in THP1 cells. Blue bars show the two individual probes used for ChIP-
QPCR in C and D. C–D H3K9me3 and H3K27me3 ChIP signal/input (fold change of NTC) in the indicated human MLLr-AML cell lines (C) and indicated
primary AML samples including PX21 (MLL-AF6) and PX30 (MLL-FA10) (D) as determined by ChIP-QPCR following depletion of KDM4A; *p < 0.001.
E Venn diagrams showing the overlap between directly bound downregulated and upregulated targets of KDM4A and the PAF1c24 in THP1 cells
following knockdown of KDM4A and PAF1 as determined by ChIPseq; p by hypergeometric test. F Motif significance and KDM4A log2 enrichment at
KDM4A or PAF1 regulated promoters (FDR ≤ 0.01, DE ≤−0.5, or DE ≥ 0.5). Color represents motif significance within KDM4A and PAF1 regulated
promoters. Size denotes the average log2 enrichment of KDM4A within each group of promoters that possess the respective transcription factor (TF)
binding motif. Top five motifs detected in KDM4A or PAF1 regulated promoters sorted by statistical significance (E-value). G GSEA results showing
significant overlap of KDM4A KD transcriptional consequences with downregulation of MLL-AF9 and HOXA9 targets and upregulation of a mature
hematopoiesis program in THP1 cells, *q < 5%.
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Fig. 6 A core 9-gene signature downstream of KDM4A strongly associated with clinical outcome. A–B Scatterplot showing the correlation
between expression of KDM4A versus PAF1 in primary AML patient samples (GSE37642) (A) and (Beat AML/Vizome), R by Pearson correlation, p< 0.05 (B).
C Kaplan-Meier survival analysis conducted in Beat AML dataset. Patients with both KDM4Ahigh and PAF1high expression have inferior overall survival. Patients
dichotomized into high and low groups for KDM4A or PAF1 based on whether expression was above the median for each gene; p by log-rank test.
D Heatmap showing gene expression of the KDM4A-9 gene signature genes with the table of their respective regression coefficients and log2 FC as
determined by RNA-seq in KDM4A KD THP1 cells. E–H Kaplan-Meier survival analysis conducted in the large AML datasets (GSE37642) (E), (Beat AML/
Vizome) (F), (GSE6891) (G), and (GSE12417) (H) showing that the KDM4A-9 score can predict survival across AML patients of varying subtypes. Patients were
dichotomized into high and low groups based on whether they possessed a score above or below the median signature score; p by log-rank test.
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Fig. 7 KDM4A-9 enriched with LSC activity, is a poor prognosis marker for AML. A Scatterplot showing a moderate correlation between the
KDM4A-9 score and LSC17 score in primary AML patient samples (GSE76008). LSC enriched (LSC+, n= 138) cell fractions from 78 patient samples are colored
blue whilst those that lack LSC enrichment (LSC−, n= 89) are colored red. Over 75% of KDM4A-9 high score (above median value) fractions are LSC+.
Pearson correlation used to assess correlation. Significance determined by t-test. B Box plot showing KDM4A-9 or LSC17 signature scores in two comparative
groups: LSC+ and LSC− from (A); unpaired t-test, *p< 0.0001. C ROC curves of KDM4A-9 (blue), LSC17 (yellow), and KDM4A-9/LSC17 (green) show the
diagnostic capability of each signature to predict LSC enrichment in AML samples. The black bars in each plot are the 95% confidence intervals for the
optimal cut-off. The Youden index was used to determine the optimal cut-off for each signature. D–E Patients in the Beat AML/Vizome dataset were
dichotomized into high and low groups based on whether they possessed a score above or below the median signature score. Kaplan-Meier survival analysis
conducted showing that the combined KDM4A-9/LSC17 score (E) is effective in the prediction of AML patient survival over the LSC17 score alone (D).
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Fig. 8 KDM4A-mediated epigenomic network required for AML cell self-renewal and survival. A Heatmap showing relative expression of
KDM4A-9 signature genes as determined by QPCR in the indicated human MLLr-AML cell lines and AML primary cells following KDM4A KD or PAF1 KD
in comparison with NTC control cells (n= 3). B Input normalized ChIP-seq coverage tracks showing KDM4A ChIP signal in WT THP1 cells and
H3K9me3/H3K27me3 ChIP signal normalized to NTC in KDM4A KD THP1 cells at KDM4A-9 signature genomic loci (+/−1 kb TSS). The normalized
signal shown is the log2 ratio of read counts compared against input control. C–D Correlation matrices showing the Pearson correlation coefficients
for KDM4A, KDM4A-9 genes, and PAF1 gene expression in GSE37642 (C) and Beat AML/Vizome (D) AML datasets. Significance determined by t-test; *p
< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. E KDM4A, PAF1, KDM4A-9 (in blue), and LSC17 (in green) gene network showing the topological overlap
between genes as detected from 262 AML samples (Beat AML) (the corresponding topological overlap matrix (TOM) ≥ 0.05 between nodes. Genes
with high topological overlap matrix (TOM) measure (TOM ≥ 0.05) have related functions).
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inappropriate genes, impeding the reprogramming of cell
identity during development and cell fate determina-
tion24,38. It would be interesting to determine further the
clinical diagnostic relevance of H3K9me3 in relation to
KDM4A in AML patients.
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